@article{2971f4b3de42453e9c9556d787b7e0fe,
title = "The structure of amyloid-β dimers in Alzheimer's disease brain: A step forward for oligomers",
author = "Bateman, \{Randall J.\} and Mawuenyega, \{Kwasi G.\} and Wildburger, \{Norelle C.\}",
note = "Funding Information: Funding for work in this paper is sup ported by the National Institutes of Health (R01NS095773, R56AG061900, R01NS065667) and an anonymous foundation. Funding Information: R.J.B. receives laboratory research funding from the National Institutes of Health (R01NS095773, R56AG061900, R01NS065667), Alzheimer{\textquoteright}s Association, BrightFocus Foundation, Rainwater Foundation Tau Consortium, Association for Frontotemporal Degeneration, the Cure Alzheimer{\textquoteright}s Fund, and the Tau SILK Consortium (AbbVie, Biogen, and Eli Lilly and Co.) Funding for clin ical trials include the National Institutes of Health (U01AG042791, R01AG046179, R01AG053267, U01AG059798, Alzheimer{\textquoteright}s Association, Eli Lilly and Company, Roche/Genentech, Janssen, Avid Radiopharmaceuticals, GHR Foundation, and an anonymous organization. R.J.B. also receives research funding from the National Institutes of Health (UF1AG032438, R13AG055232, U19AG010483) and the DIAN-TU Pharma Consortium (AbbVie, Amgen, AstraZeneca, Biogen, Eisai, Elan, Eli Lilly and Co./ Avid Radiopharmaceuticals, Forum Pharmaceuticals, Roche/Genentech, Janssen, Mithridion, Novartis, Pfizer, and Sanofi). R.J.B. reports consulting fees/honoraria from AC Immune, Johnson \& Johnson, Pfizer, Eisai, Roche, and Merck. R.J.B. reports equity ownership interest/advisory board income from C2N Diagnostics.",
year = "2019",
month = may,
day = "1",
doi = "10.1093/brain/awz082",
language = "English",
volume = "142",
pages = "1168--1169",
journal = "Brain",
issn = "0006-8950",
number = "5",
}